Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 489-501

  Hoffmann, Matthew ^a   Kasserra, Claudia ^c   Reyes, Josephine ^c   Schafer, Peter ^b   Kosek, Jolanta ^b   Capone, Lori ^b   Parton, Anastasia ^b   Kim Kang, Heasook ^d   Surapaneni, Sekhar ^a   Kumar, Gondi ^a  

^a Drug Metabolism and Pharmacokinetics Department   (United States)

^b Translational Development Department   (United States)

^c Celgene   (United States)

^d XENOBIOTIC LABORATORIES INC   (United States)

Author keywords

IMiDs; Metabolism; Pharmacokinetics; Pomalidomide; Urinary excretion

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DRUG METABOLITE; POMALIDOMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG URINE LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, ORAL; ADULT; CARBON RADIOISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MALE; PHENOTYPE; THALIDOMIDE; YOUNG ADULT;

EID: 84874110472     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2040-6     Document Type: Article

References (10)

1. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326-2335. doi: 10.1038/leu.2012.119
2. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22(16):3269-3276
3. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57(5):465-480
4. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH, Mendy D, Lopez-Girona A, Tran T, Sapinoso L, Fang W, Xu S, Hampton G, Bartlett JB, Schafer P (2010) Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 10(2):155-167
5. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159(4):842-855
6. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT (2004) Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687-688
7. McHugh SM, Rowland TL (1997) Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-α) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 110:151-154
8. Surapeneni S, Stoltz M, Hilhorst M, Kumar G, Laskin O (2009) Mass balance, metabolism and excretion of 14C-thalidomide in healthy human subjects. Drug Metab Rev 41(S3):66-67
9. 14C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemother Pharmacol 69:789-797
10. Varma MVS, Feng B, Obach S, Troutman MD, Chupka J, Miller HR, El-Kattan A (2009) Physicochemical determinants of human renal clearance. J Med Chem 52:4844-4852